奥米克斯集成确定了CRIP2作为前列腺癌中olaparib耐药性的关键调解者
Weicheng Tian1,2, Yize Li1,2,3, Haiyin Xiao4
1Guangdong Provincial Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Translational andrology and urology
|October 24, 2025
概括
这项研究确定了特定的瘤细胞亚群,在割抵抗性前列腺癌 (CRPC) 中驱动Olaparib耐药性. 开发的风险模型和识别的CRIP2基因为个性化治疗提供了新的策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 对于像Olaparib这样的多聚ADP-ribose聚合酶抑制剂 (PARPis) 的耐药性机制,在割耐性前列腺癌 (CRPC) 后雄激素剥夺疗法 (ADT) 中尚不清楚.
- 导致CRPC中Olaparib耐药性的瘤上皮细胞亚群需要系统识别.
研究的目的:
- 在CRPC中识别与Olaparib耐药性相关的瘤上皮细胞亚群.
- 开发一种预后风险模型来预测Olaparib耐药性.
- 为了研究关键基因在Olaparib耐药性中的作用.
主要方法:
- 集成的单细胞RNA测序 (scRNA-seq),空间转录组学 (ST) 和大量RNA测序 (RNA-seq).
- 采用了Scissor和BayesPrism算法来识别与阻力相关的子群 (Scissor+) 和它们的比例.
- 使用机器学习算法构建了一个olaparib耐药性相关基因 (ORAG) 风险模型.
- 通过体外试验验证了CRIP2在Olaparib耐药性的作用.
主要成果:
- 确定了与Olaparib耐药性显著相关的剪刀+上皮细胞亚群.
- 增加的剪刀+细胞比例与预后不佳相关 (P=0.04).
- ORAG风险模型显示出强大的预后性能 (C指数=0.722).
- CRIP2被确定为关键的风险基因,与更糟糕的预后和更高的瘤阶段,格里森得分和PSA水平有关.
- 在体外,CRIP2 knockdown增加了对Olaparib的敏感性.
结论:
- 在CRPC中使用多omics数据首次系统地识别了Olaparib耐药性相关的瘤细胞亚群.
- ORAG风险模型显示了临床应用的潜力,用于预测Olaparib耐药性.
- CRIP2成为抗药性的关键因素,为CRPC提供了新的治疗策略.
相关概念视频
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


